The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts

Oral Oncology

Volumn 47, Issue 5, 2011, Pages 340-344

  Bozec, Alexandre ^a   Etienne Grimaldi, Marie Christine ^a   Fischel, Jean Louis ^a   Sudaka, Anne ^a   Toussan, Nicolas ^a   Formento, Patricia ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Anti angiogenic agents; Anti EGFR agents; Head and neck cancer; Irradiation; mTOR inhibitors

Indexed keywords

BEVACIZUMAB; CETUXIMAB; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956198835     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.02.020     Document Type: Article

References (30)

1. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21(Suppl. 7):252-61.
2. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007;97:65-72. (Pubitemid 47012080)
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
4. Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/ Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 2006;66:2889-92.
5. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17:487-94. (Pubitemid 44309964)
6. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005;65:9953-61. (Pubitemid 41541476)
7. Nathan C-AO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007;67:2160-8. (Pubitemid 46424235)
8. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9. (Pubitemid 46452288)
9. Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L, et al. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer 2009;9:161-75.
10. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, Kim IH, et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 2010;8:1027-36.
11. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon M-F, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (Iressa). Br J Cancer 2002;86:1518-23. (Pubitemid 34548078)
12. Bozec A, Lassalle S, Guggenheim J, Fischel JL, Formento P, Hofman P, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006;95:722-8. (Pubitemid 44373488)
13. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
15. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent Cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8. (Pubitemid 46638804)
16. Shang ZJ, Li ZB, Li JR. VEGF is upregulated by hypoxic regulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg 2006;35:533-8.
17. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008;28:1659-66. (Pubitemid 351892941)
18. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-8.
19. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010;65:649-60.
20. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 2009;1:6.
21. Jiang B-H, Liu L-Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008;11:63-76.
22. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/ mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32-50.
23. Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, et al. Simultaneous blockade of the epidermal growth factor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 2009;8:1547-56.
24. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30. (Pubitemid 351341618)
25. Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC, et al. Phase I/II: trial of CCI- 779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 2007;25(Suppl):Abstract 5034.
26. Hainsworth JD, Spigel DR, Burris 3rd HA, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28:2131-6.
27. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff Jr CL. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008;68:4392-7.
28. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-22. (Pubitemid 43080085)
29. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009;15:589-96.
30. Shinohara ET, Maity A, Jha N, Lustig RB. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck 2009;31:406-11.